OraSure Technologies (OSUR) Receives Analyst Rating

OraSure Technologies (OSUR) : The consensus on OraSure Technologies (OSUR) based on 3 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.


Also, Equity analysts at the Brokerage firm Stephens & Co. upgrades its rating on OraSure Technologies (NASDAQ:OSUR). The rating major has initiated the coverage with overweight rating on the shares. Earlier, the shares were rated a Equal-weight by the brokerage firm. The rating by the firm was issued on August 29, 2016.

OraSure Technologies (NASDAQ:OSUR): After opening at $8.64, the stock dipped to an intraday low of $8.55 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.77 and the buying power remained strong till the end. The stock closed at $8.68 for the day, a gain of 0.93% for the day session. The total traded volume was 872,406. The stocks close on the previous trading day was $8.6.

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test, OraQuick ADVANCE, OraSure HIV-1 oral specimen collection device, OraQuick HCV rapid antibody test, Intercept oral fluid drug testing system, OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary, DNA Genotek Inc., the Company provides oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.